GlassScriptPhysician profile
Jennifer A Cunningham
NPI 1700813599
$4,524.27
in general payments reported to CMS, 2019-2025
45 companies · $839 in 2025
The $839 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $460 · 2021: $718 · 2022: $552 · 2023: $587 · 2024: $725 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $541.18 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $471.75 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $392.09 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $368.34 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $356.66 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $306.61 | 2019-2025 | |
| Intuitive Surgical, INC. | $225.51 | 2019-2025 | |
| Shield Therapeutics INC | $158.67 | 2023-2025 | Accrufer |
| Sage Therapeutics, LLC | $139.54 | 2024-2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $123.99 | 2020-2022 | |
| Hologic Sales and Service, LLC | $107.57 | 2019-2025 | Aptima, Acessa Provu System |
| Exeltis, USA INC. | $101.69 | 2019-2024 | Slynd |
| Baxter Healthcare | $97.62 | 2021-2025 | Perclot, Tisseel |
| Myovant Sciences INC. | $89.28 | 2021-2022 | |
| Therapeuticsmd, INC. | $88.73 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $86.93 | 2022-2025 | Nexplanon, Jada System |
| Meditrina | $62.76 | 2022-2023 | |
| Coopersurgical, INC. | $61.90 | 2022-2025 | Endosee, Paragard T 380a |
| Astrazeneca Pharmaceuticals LP | $61.16 | 2019 | |
| Evofem Biosciences, INC. | $60.30 | 2021-2025 | Phexxi, Solosec, Phexx |
| Ethicon US, LLC | $50.43 | 2020-2021 | |
| Agile Therapeutics, INC. | $49.16 | 2021-2022 | |
| Scynexis, INC. | $42.94 | 2022 | |
| Lsi Solutions INC | $39.19 | 2021-2023 | Fornisee |
| Millicent US INC | $36.61 | 2024-2025 | Intrarosa, Femring |
| Monaghan Medical Corporation | $33.19 | 2024 | Aerobika |
| Novo Nordisk INC | $32.18 | 2024-2025 | Wegovy, Ozempic |
| Channel Medsystems, INC. | $28.97 | 2025 | |
| Endo Pharmaceuticals INC. | $28.60 | 2019-2021 | |
| Avion Pharmaceuticals | $26.20 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $25.85 | 2019 | |
| Northgate Technologies, INC. | $24.12 | 2024 | Stimsite |
| Supernus Pharmaceuticals, INC. | $22.80 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $19.61 | 2019 | |
| Biom'Up France Sas | $18.75 | 2021 | |
| Caldera Medical, INC | $17.17 | 2023 | Desara |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2019 | |
| Mission Pharmacal Company | $15.48 | 2019 | |
| Becton, Dickinson and Company | $14.72 | 2024 | Bd Max System, Bd Max Instrument |
| Idorsia Pharmaceuticals US INC | $14.34 | 2023 | Quviviq |
| Coloplast Corp | $14.22 | 2021 | |
| Davol INC. | $14.03 | 2020 | |
| Merck Sharp & Dohme LLC | $13.11 | 2023 | Gardasil 9 |
| Lupin INC. | $12.35 | 2019 | |
| Amgen INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.